Keratoacanthoma
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Aṣoju Keratoacanthoma
References
Keratoacanthoma (KA) jẹ tumọ awọ ara loorekoore ti a mọ fun idagbasoke iyara rẹ ati agbara lati tun pada funrararẹ. O maa nwaye ni agbalagba, awọn ọkunrin ti o ni awọ ara ti o ni itanjẹ ti ibajẹ oorun. Lakoko yiyọkuro iṣẹ-abẹ nipa lilo imukuro tabi iṣẹ abẹ micrographic Mohs jẹ itọju igbagbogbo, ọpọlọpọ awọn aṣayan itọju ailera miiran wa.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) jẹ tumo-kekere ti o bẹrẹ ni awọn keekeke kan ninu awọ ara ati pe o dabi squamous cell carcinoma (SCC) labẹ microscope kan. Jomitoro ti nlọ lọwọ nipa boya KA yẹ ki o jẹ ipin bi fọọmu ti SCC afomo.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) jẹ iru keji ti o wọpọ julọ ti akàn ni awọn eniyan, paapaa laarin awọn agbalagba. Iṣẹ abẹ ni a maa n lo lati tọju cSCC, ṣugbọn fun diẹ ninu awọn alaisan ti ko le ṣe iṣẹ abẹ tabi yan lati ma ṣe, awọn aṣayan miiran bi awọn itọju inu inu le ṣee gbero. Awọn itọju intralesional ti aṣa (methotrexate or 5-fluorouracil) ni a ti lo, ṣugbọn iwadii ti nlọ lọwọ lori awọn ọna tuntun bii imunotherapy intralesional ati oncolytic virotherapy. Ninu eyi, a yoo wo oriṣiriṣi awọn itọju intralesional fun cSCC, ti o wa lati awọn ọna alailẹgbẹ si awọn ilana gige-eti.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Labẹ maikirosikopu, keratoacanthoma ni pẹkipẹki dabi carcinoma cell squamous. Lakoko ti diẹ ninu awọn onimọ-jinlẹ ṣe iyasọtọ keratoacanthoma gẹgẹbi nkan ti o yatọ ati kii ṣe aiṣedeede, nipa 6% ti ile-iwosan ati itan-akọọlẹ keratoacanthoma ṣe ilọsiwaju si awọn aarun aarun alakan ati ibinu squamous.
○ Ayẹwo ati Itọju
#Dermoscopy
#Skin biopsy